1043P NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma

Abstract

Three genomic subtypes of BRAF wildtype (WT) cutaneous melanoma (CM) include NRAS mutant (mut), NF1 mut, triple wildtype (tWT). NF1 mut melanoma have a high tumor mutation burden and have been associated with increased responsiveness to immune checkpoint inhibitors (ICI) in some retrospective studies. We evaluated whether the NF1 subtype was associated with improved ICI outcomes in our population.